Zota Health Care Ltd
📡AI Radar📊 Stock Analysis
Market Data
Face Value₹10
Performance
ROCE-12.45 %
ROE-14.88 %
EPS (TTM)₹-12.58
EPS Prev Qtr₹-4.13
EPS Last Year₹-5.26
EBITDA Qtr₹-39.35 Cr.
Financial Health
Debt/Equity0.04
Debt/Profit-0.28
Total Assets₹1,131.051 Cr.
Promoter Holding49.38 %
Earning Power-8.18 %
Valuation
Industry P/E33.81
Key Metrics
__derived
1
Face Value
₹10
About Zota Health Care Ltd
Healthcare · Pharmaceuticals
Zota Health Care Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10.
Strengths & Weaknesses
Strengths
- The company maintains a low debt-to-equity ratio of 0.04, indicating minimal financial leverage.
- Promoter holding stands at 49.38%, suggesting significant control and alignment of interests by management.
Weaknesses
- The company reported a net loss of ₹104.23 Cr, indicating unprofitable operations.
- ROCE is -12.45%, showing poor return on capital employed.
- ROE is -15.03%, reflecting negative return on equity for shareholders.
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.51 | ₹4,41,477.63 Cr | 0.87% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 86.48 | ₹2,53,031.38 Cr | 0.31% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 77.67 | ₹1,85,216.32 Cr | 0.78% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 27.01 | ₹1,20,897.46 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.28 | ₹1,12,201.64 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 99.31 | ₹1,08,698.22 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Dr Reddys Laboratories Ltd | - | 31.6 | ₹1,02,039.12 Cr | 0.65% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Mankind Pharma Ltd | - | 49.29 | ₹1,00,752.43 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Aurobindo Pharma Ltd | - | 26.56 | ₹97,814.24 Cr | 0.24% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.64 | ₹94,274.49 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 36.67 | ₹65,922.11 Cr | 0.11% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 28.65 | ₹61,804.34 Cr | 1.03% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 110.29 | ₹61,113.53 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.22 | ₹56,860.69 Cr | 1.78% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 46.73 | ₹49,091.33 Cr | 1.97% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ipca Laboratories Ltd | - | 36.13 | ₹48,712.48 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 83.03 | ₹47,949.68 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Gland Pharma Ltd | - | 42.26 | ₹47,764.08 Cr | 0.69% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ajanta Pharma Ltd | - | 38.87 | ₹44,109.77 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
📊 Jun 2026: Revenue grew 67.6% YoY, Profit fell 218.9% YoY
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 103.58 | 128.95 | 142.95 | 163.18 | 173.6 |
| ↳ QoQ Growth | - | +24.5% | +10.9% | +14.2% | +6.4% |
| Expenses | 114.3 | 141.14 | 165.65 | 181.48 | 212.95 |
| Operating Profit | -10.72 | -12.19 | -22.7 | -18.31 | -39.35 |
| OPM % | -10.35% | -9.45% | -15.88% | -11.22% | -22.67% |
| Other Income | 0.87 | 1.64 | 1.72 | 3.21 | 2.04 |
| Interest | 3.24 | 3.83 | 4.97 | 5.32 | 6.35 |
| Depreciation | 14.68 | 18.51 | 22.26 | 27.01 | 27.75 |
| EBITDA | 3.96 | 6.32 | -0.44 | 8.7 | -11.6 |
| EBITDA Margin % | 3.82% | 4.9% | -0.31% | 5.33% | -6.68% |
| Profit Before Tax | -13.08 | -14.38 | -25.95 | -26.42 | -43.65 |
| Tax % | -5.35% | -12.59% | -14.22% | 45.27% | -0.66% |
| Net Profit | -13.78 | -16.19 | -29.64 | -14.46 | -43.94 |
| ↳ QoQ Growth | - | -17.5% | -83.1% | +51.2% | -203.9% |
| EPS | -4.88 | -5.26 | -9.44 | -4.13 | -12.58 |
Profit & Loss
| Mar 2026 | TTM | |
|---|---|---|
| Sales | 538.66 | 608.68 |
| Expenses | 602.57 | 701.22 |
| Operating Profit | -63.92 | -92.55 |
| OPM % | -11.87% | -15.21% |
| Other Income | 7.44 | 8.61 |
| Interest | 17.36 | 20.47 |
| Depreciation | 82.46 | 95.53 |
| Profit Before Tax | -79.83 | -110.4 |
| Tax % | 7.22% | 5.59% |
| Net Profit | -74.07 | -104.23 |
| EPS | -23.71 | -31.41 |
Compounded Sales Growth
10Y
-
5Y
-
3Y
-
TTM
-
Compounded Profit Growth
10Y
-
5Y
-
3Y
-
TTM
-
Stock Price CAGR
10Y
-
5Y
-
3Y
-
1Y
-
Return on Equity
10Y
-
5Y
-
3Y
-
Last Year
-15.03%
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 28.64 | 34.6326 |
| Reserves | 195.05 | 658.8567 |
| Borrowings | 139.6 | 28.73 |
| Other Liabilities | 75.85 | 408.83 |
| Total Liabilities | 439.14 | 1131.0514 |
| Fixed Assets | 181.37 | 382.865 |
| CWIP | 5.58 | 1.7106 |
| Investments | 54.35 | 263.88 |
| Other Assets | 197.84 | 482.6 |
| Total Assets | 439.14 | 1131.0514 |
Cash Flows
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Cash from Operating Activity | -49.9642 | -81.8455 |
| Cash from Investing Activity | -92.1859 | -329.6417 |
| Cash from Financing Activity | 144.7635 | 503.4413 |
| Net Cash Flow | 2.6134 | 91.9541 |
Ratios
| Mar 2026 | |
|---|---|
| Debtor Days | - |
| Inventory Days | - |
| Days Payable | - |
| Cash Conversion Cycle | - |
| Working Capital Days | 746.94 |
| ROCE % | -5.8% |
Shareholding Pattern
| Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Promoters % | 55.81% | 50.64% | 49.38% | 49.38% |
| FIIs % | 3.49% | 8.09% | 7.88% | 7.92% |
| DIIs % | 0.06% | 7.22% | 7.04% | 6.75% |
| Public % | 25.25% | 26.16% | 27.84% | 28.2% |
| No. of Shareholders | 11,855 | 13,185 | 14,005 | 14,678 |
Major Shareholders (>1%)
- Himansubhai Muktilal ZotaPromoter and Promoter Group9.05%
- Ketankumar Chandulal ZotaPromoter and Promoter Group8.81%
- Manukant Chandulal ZotaPromoter and Promoter Group6.27%
- Kamlesh Rajanikant ZotaPromoter and Promoter Group5.75%
As of 2026-06-30View all shareholders →